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Abstract
Prostate cancer, the second most frequently diagnosed cancer in males worldwide, is estimated to be diagnosed in
1.1 million men per year. Introduction of PSA testing substantially improved early detection of prostate cancer,
however it also led to overdiagnosis and subsequent overtreatment of patients with an indolent disease. Treatment
outcome and management of prostate cancer could be improved by the development of non-invasive biomarker
assays that aid in increasing the sensitivity and specificity of prostate cancer screening, help to distinguish aggressive
from indolent disease and guide therapeutic decisions. Prostate cancer cells release miRNAs into the bloodstream,
where they exist incorporated into ribonucleoprotein complexes or extracellular vesicles. Later, cell-free miRNAs have
been found in various other biofluids. The initial RNA sequencing studies suggested that most of the circulating
cell-free miRNAs in healthy individuals are derived from blood cells, while specific disease-associated miRNA signatures
may appear in the circulation of patients affected with various diseases, including cancer. This raised a hope that
cell-free miRNAs may serve as non-invasive biomarkers for prostate cancer. Indeed, a number of cell-free miRNAs that
potentially may serve as diagnostic, prognostic or predictive biomarkers have been discovered in blood or other
biofluids of prostate cancer patients and need to be validated in appropriately designed longitudinal studies and
clinical trials. In this review, we systematically summarise studies investigating cell-free miRNAs in biofluids of prostate
cancer patients and discuss the utility of the identified biomarkers in various clinical scenarios. Furthermore, we discuss
the possible mechanisms of miRNA release into biofluids and outline the biological questions and technical challenges
that have arisen from these studies.
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Background
Prostate cancer is a global health problem. Approxi-
mately 1.1 million cases are diagnosed per year, making
this malignancy the second most common cancer in
men worldwide and the most common cancer in men in
more developed regions [1, 2]. In terms of mortality,
prostate cancer is the fifth leading cause of death from
cancer in men [1, 2].
In the economically developed countries, over 80 % of
prostate cancer cases are diagnosed at localised stage [3],
when the disease can often be cured by localised therapies
such as radical prostatectomy and radiotherapy. Technical
developments in radical prostatectomy as well as targeted
external beam radiation therapy have significantly reduced
patient morbidity after curative treatment. Cancer specific
survival 5 years after the time of diagnosis is high for local-
ised prostate cancer, and it reaches almost 100 % in USA
according to the American Cancer Society. However, the
more advanced the cancer at diagnosis, the poorer the
prognosis. When metastatic prostate cancer is diagnosed,
androgen deprivation is the initial line of therapy. Andro-
gen deprivation therapy (ADT), however, is a palliative and
not a curative treatment for patients with metastases, and
eventually the patients will develop metastatic castration-
resistant prostate cancer (mCRPC), for which currently
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available treatment options have limited efficacy [4, 5].
Once the disease is androgen independent, the estimated 5-
year survival drops to 28 % and the average survival time is
2 years [4].
The discovery of prostate specific antigen (PSA) al-
most 30 years ago has changed the way how prostate
cancer is diagnosed and managed. The serum PSA test
is currently the most commonly used tool for organised
screening programs, opportunistic screening and moni-
toring of prostate cancer. Evidence obtained in numer-
ous clinical trials suggests that the PSA test may
improve the early detection of localised prostate cancer,
however it has substantial drawbacks due to overdiagno-
sis and overtreatment. The balance of benefits and
harms is still a matter of active debate, and improving
the performance of PSA-based screening for prostate
cancer is essential [6–8]. Furthermore, recent advances
in the development of therapeutics for prostate cancer
have raised the necessity for biomarkers that can predict
treatment outcome and be used in therapeutic decisions.
It is clear that there is clinical need for novel prostate
cancer biomarkers. The identification of cancer bio-
markers that can be measured in a noninvasive way, for
example in a blood or urine sample, is of particular im-
portance as these samples can be easily acquired
throughout the course of the disease. These biomarkers,
often referred as circulating biomarkers or liquid biop-
sies [9], may better reflect the heterogeneity of the
tumour than single biopsies.
In 2008, three independent studies demonstrated that
tumour-associated miRNAs are released into the blood
circulation and are present in human plasma and serum
in a remarkably stable form [10–12]. More recently, cell-
free miRNAs have also been found in a variety of other
biofluids [13–15]. Given that miRNA expression pat-
terns are tissue and cancer-type specific [16, 17], these
findings led to the concept that different cancers may
leave specific miRNA signatures in biofluids [12], and
that these signatures may carry information about the
disease status, aggressiveness and response to therapy.
This concept has attracted enormous attention of re-
searchers resulting in the discovery of cell-free miRNA
signatures with diagnostic, prognostic and predictive
relevance for various types of cancer, including prostate
cancer. In the current review, we systematically summar-
ise studies exploring cell-free miRNAs in biofluids of
prostate cancer patients, propose their clinical utility in
various clinical scenarios and discuss mechanisms for
miRNA release in biofluids.
Unmet clinical needs in the management of prostate
cancer
Prostate cancer is a multi-faceted disease and clinicians
treating and managing the disease face several challenges
at the different clinical states [18]. The first decision
point is the early detection of localised tumours. Since
prostate cancer symptoms generally appear at advanced
stages of the disease, PSA-based screening seemed an
appealing idea and many countries launched population-
based screening programs in the early 1990s [6–8]. A
combination of high PSA levels in blood and a positive
digital rectal exam typically leads to a biopsy to confirm
diagnosis and determine the Gleason grade. PSA-based
screening indeed has proved useful in detecting early
stage prostate cancer and has been shown to reduce the
rate of death from prostate cancer in some studies [19].
However, PSA is not cancer specific – it is a glycopro-
tein produced by normal prostate epithelial cells at equal
or higher levels than by cancer cells and released into
the bloodstream due to increased epithelial barrier per-
meability and cellular reorganisation [20]. Elevated
serum PSA levels can be found not only in men with
prostate cancer, but also in men with benign prostatic
hyperplasia (BPH) and prostatitis [21–23]. Moreover, a
variety of factors such as ejaculation, prostate biopsy,
acute urinary retention and even bicycle riding may
transiently increase PSA levels [24, 25]. In fact, several
initial studies have demonstrated that only 22–26 % of
men with elevated PSA levels (4.0–9.9 ng/ml) have can-
cer [26–28]. High false positive rate and low specificity
of the PSA test consequently leads to large numbers of
unnecessary prostate biopsies and emotional morbidity
[8, 29–31]. The PSA-based test also gives a high rate of
false negatives. For instance, a study by Thompson et al.
involving 2950 men with PSA levels ≤4.0 ng/ml showed
that 15.2 % of them had a biopsy-detected prostate can-
cer [32]. Several alternative approaches for improving
the diagnostic performance of PSA have been suggested,
including PSA velocity, PSA density, age-specific PSA
levels and free to total PSA ratio [33]. However all
these tests have their own advantages and drawbacks,
and their clinical utility has not been validated in
randomised trials so far. Hence, additional or alterna-
tive biomarkers that could increase the sensitivity and
specificity of prostate cancer screening still represent
an unmet clinical need.
The data about the impact of PSA-based screening on
prostate cancer mortality are controversial. While the
European Randomized Study of Screening for Prostate
Cancer that was initiated in the early 1990s and involved
182,000 men concluded that PSA-based screening re-
duced the death rate by 20 % [6, 19], the Prostate, Lung,
Colorectal, and Ovarian (PLCO) Cancer Screening Trial
that was carried out in the USA between 1993 and 2001
and enrolled 76,685 men found no evidence of reduced
mortality [7]. The reason for such a discrepancy is not
yet clear. Both studies, however, concluded that orga-
nised PSA-based screening is associated with high risk
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of overdiagnosis. In line with this conclusion, a recent
Norwegian study focusing on the effects of opportunistic
PSA testing on trends in stage distribution in different
age groups observed a considerable increase in the inci-
dence of localised prostate cancer in younger men, and a
moderate decrease in the incidence of advanced cancer
in older men, but that did not fully compensate the ini-
tial increase [29]. Overdiagnosis refers to the detection
of indolent cancers that most likely would never have
become clinically significant and leads to aggressive
treatments with substantial side effects [29, 34]. The
overdiagnosis rate for annual PSA-based screening has
been estimated to be approximately 50 %, and it is con-
sidered to be the most significant harm of screening
[29, 34]. Once early stage prostate cancer is detected,
the second decision point is to choice between radical
treatment and active surveillance. Management deci-
sions are based on risk stratification systems. For ex-
ample, the D’Amico risk system stratifies the patients in
low-, intermediate- and high-risk groups for recurrence
after curative treatment based on PSA levels, Gleason
score, and tumour stage [35]. However, actual risk clas-
sification systems (D’Amico risk-group classification,
National Comprehensive Cancer Network, CAPRA
score) often give different results and are not sufficient
to distinguish true indolent from clinically significant
prostate cancer thus resulting in many patients with in-
dolent cancers being treated. There is a clear unmet
need for biomarkers that can reduce overtreatment.
The third decision point is the choice of treatment
for metastatic prostate cancer. The standard treatment
for metastatic hormone-sensitive prostate cancer is
ADT. Although most of the patients initially respond
well, the disease ultimately becomes resistant and re-
curs within 1–3 years as mCRPC [4, 36]. Three recent
clinical trials evaluated the effect of the addition of
various chemotherapeutic agents to ADT – two of
these studies, STAMPEDE [37] and CHAARTED [38],
showed significant survival benefit for patients receiv-
ing ADT in combination with docetaxel, while the third
study, GETUG-AFU 15, observed a trend towards im-
proved survival, however it did not reach a statistical
significance [39]. For mCRPC, the first-line therapy
currently is docetaxel-based chemotherapy, which pro-
vides modest survival benefits (approximately
2.4 months compared with mitoxantrone-based ther-
apy) and improve the quality of life in approximately
22 % of patients [40]. In the past five years, several
novel chemotherapeutic (cabazitaxel) and radiopharma-
ceutical (radium-223) agents, androgen receptor-
targeted agents (abiraterone acetate, and enzalutamide)
and an immunotherapeutic approach (sipuleucel-T)
have been approved for the management of mCRPC, all
of them have been shown to improve overall survival
by 3–5 months [41, 42]. More recently, several novel
therapeutic agents targeting DNA-repair defects (Olaparib)
[43], bone microenvironment and metastasis formation
(Tasquinimod) [44], resistance pathways (Custirsen) [45]
and mesenchymal-epithelial transition (Cabozantinib) [46]
have been shown to have antitumour activity and survival
benefits in subgroups of patients [47]. Therefore, the identi-
fication of biomarkers that could predict patients’ response
to specific therapies and could help to select the optimal
combination of agents or treatment schedule is becoming
increasingly important [48].
miRNAs are found in biofluids
miRNAs are a class of endogenous 19–22 nucleotides
long, single-stranded non-coding RNA molecules. These
small RNAs post-transcriptionally regulate gene expres-
sion by base-pairing to the complementary sites in their
target mRNAs resulting either in the degradation of the
target mRNAs or in the inhibition of translation initi-
ation [49, 50]. The current release of miRBase (June,
2014) contains 1881 precursors and 2588 mature human
miRNA sequences [51]. miRNA expression profiles have
been found to be tissue type-specific and frequently dys-
regulated in various cancers. Importantly, they may ro-
bustly distinguish tumours from normal tissues and
classify tumours according to the developmental lineage,
differentiation state and aggressiveness [16, 52]. In pros-
tate cancer, miRNA signatures that distinguish malig-
nant from normal tissues, low- from high-risk cancers
and recurrent from non-recurrent cancers have been
identified [53–56].
Mitchell et al. demonstrated for the first time that
miRNAs from human prostate cancer xenografts were
released into the circulation of xenograft-bearing mice
and could be readily detectable in the plasma once the
tumours were established [11]. This study also showed
that miRNAs in human plasma remain stable after incu-
bation of plasma at room temperature for up to 24 h or
multiple freeze-thaw cycles. Furthermore, serum levels
of miR-141 were substantially higher in patients with
metastatic prostate cancer than healthy controls and dis-
tinguished cases from controls with a sensitivity of 60 %,
specificity of 100 % and an area under the curve (AUC)
of 0.907 [11].
Cell-free miRNAs have been subsequently found in
various human body fluids including blood, urine, tears,
breast milk, bronchial lavage, colostrums, and also in
seminal, amniotic, pleural, peritoneal and cerebrospinal
fluid [13, 14, 57]. The highest number of detectable miR-
NAs was found in saliva, seminal fluid and breast milk,
while urine, pleural fluid and cerebrospinal fluid had the
lowest number of different miRNAs. The most abundant
miRNAs were typically found in most of the biofluids,
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however there are miRNAs that were uniquely detected
in a particular biofluid [13].
In biofluids and cell culture media, cell-free miRNAs
have been found to be packaged into extracellular vesi-
cles (EVs) [58–62], or to exist in a vesicle-free form asso-
ciated with proteins such as Argonaute2 [63, 64] and
nucleophosmin [65], or high-density lipoproteins [66]
(Fig. 1).
The proportion of vesicle-enclosed and vesicle-free
miRNAs in biofluids is still a controversial issue. A study
by Arroyo et al. demonstrated that only a minority of
cell-free miRNAs in human plasma and serum are asso-
ciated with EVs, while approximately 90 % of miRNAs
are incorporated in Argonaute2 containing ribonucleo-
protein complexes. Moreover, some miRNAs were exclu-
sively associated with vesicles and others with
ribonucleoprotein complexes [63]. The same group later
performed a stoichiometric analysis of the miRNA con-
tent of exosomes isolated from various sources and
found on average 0.00825 miRNA molecules per exo-
some. The authors proposed two models for exosomal
RNA content: one suggests that a small fraction of exo-
somes carries a low concentration of miRNA and the
other that very rare exosomes carry many copies of a
given miRNA [67]. On the contrary, a study by Gallo
et al. showed that the concentration of miRNAs was
consistently higher in exosomal fractions as compared to
exosome-depleted serum and saliva [68]. Cheng et al.
performed deep sequencing of miRNAs in exosomal and
total cell-free RNA fractions in human plasma and
serum and found that exosomes are enriched in miRNAs
and provide a consistent source of miRNAs for bio-
marker discovery [69]. Similarly, deep sequencing of
exosomal and total cell-free small RNAs in human urine
showed a significant enrichment of miRNAs in exo-
somes [69] and the level of exosomal, but not vesicle-
free, miR-373 has been shown to be increased in patients
with breast cancer [70]. It is important to note that all
these studies are not directly comparable as they differ
in the EV isolation methods, RNase and proteinase K
treatment and possibly pre-analytical variables.
EV-mediated miRNA release
The term “EV” refers to virtually any type of lipid
bilayer-bound vesicle released into the extracellular
space by any type of cell. EVs differ in their biogenesis,
molecular content, size, membrane composition, cellular
source and specific functions. According to the mode of
biogenesis, three main types of EVs have been defined:
(i) exosomes, (ii) microvesicles (MVs) and (iii) apoptotic
bodies [71, 72] (Fig. 1). Exosomes are the smallest (30–
150 nm) vesicles and formed via inward budding of
endosomal membranes, resulting in multivesicular bod-
ies (MVB) that later fuse with the plasma membrane
Fig. 1 Different mechanisms of cell-free miRNA release from cancer cells. miRNAs can be released from cells and enter the bloodstream, urine or
seminal fluid either in the form of membrane-enclosed vesicles (i.e., exosomes, microvesicles, apoptotic bodies and large oncosomes) that differ in size and
molecular content or vesicle-free forms, where miRNAs are bound to specific RNA binding proteins or packaged in high density lipoprotein complexes.
AGO2, argonaute2; NPM1, nucleophosmin 1; MVB, multivesicular body
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releasing their internal vesicles/exosomes into the
extracellular environment [73, 74]. Microvesicles are
larger (50–1000 nm) vesicles generated by outward
budding and fission of the plasma membrane [75, 76].
Apoptotic bodies are produced by dying cells during
the late stages of apoptosis, when cells disassemble into
membrane-bound vesicles ranging in size from 50 nm
to 5 μm [73, 77]. Apoptotic bodies are promptly cleared
by phagocytes in vivo and their main biological func-
tion is to facilitate the removal of aged or damaged
cells and to prevent the leakage of their intracellular
content in the extracellular space, thus minimising tis-
sue damage and preventing the development of chronic
inflammatory and autoimmune diseases [78]. More re-
cently, atypically large EVs (1–10 μm), termed “large
oncosomes”, were found to be generated by the shed-
ding of non-apoptotic plasma membrane blebs from
fast-migrating prostate cancer cells that had acquired
an amoeboid phenotype known to be associated with
aggressive or metastatic disease [79–81]. These vesicles
were shown to harbour cancer-promoting bioactive
molecules and to be more abundant in plasma of pa-
tients with metastatic prostate cancer in comparison to
localised cancer, therefore they may be of particular im-
portance as prognostic biomarkers [80, 82, 83]. It is not
clear at the moment if large oncosomes represent a
new type of EVs or a subtype of MVs.
EVs have been shown to contain a large variety of
small non-coding RNA species, including miRNAs,
tRNAs, snoRNAs, snRNAs, mitochondrial-associated
RNA, piRNAs, vault RNAs and Y-RNAs, as well as
mRNAs, lncRNAs and rRNAs [58, 59, 62, 84, 85]. Ap-
parently, the EV RNA content is not merely a reflection
of cellular RNA content, and some specific small RNAs
are selectively exported to EVs, while others are ex-
cluded [85, 86]. Furthermore, the repertoire and propor-
tions of various RNAs seems to differ between various
types of EVs [80, 87, 88]. For example, in a recent study
Lunavat et al. compared the small RNA content in exo-
somes, MVs and apoptotic bodies released by melanoma
cells and found that exosomes were relatively enriched
in small RNAs, while MVs and apoptotic bodies con-
tained a larger proportion of rRNAs. Deep sequencing of
miRNAs revealed a set of 113 miRNAs that were shared
between all types of EVs and cells, a set of 23 miRNAs
that were only detected in exosomes and a distinct set of
26 miRNAs that were shared between MVs, apoptotic
bodies and cells, but not found in exosomes [87]. Hence,
the sorting signals and mechanisms are likely to be dif-
ferent in distinct types of EVs. In this regard, several
sorting mechanisms have been proposed. A study by
Gibbings et al. demonstrated that GW182, a component
of the RNA-inducing silencing complex, is localised in
endosomal/MVB membranes and secreted in exosomes
and thus it may be implicated in the loading of miRNAs
into exosomes [89]. Later, Villarroya-Beltri et al. reported
the identification of short sequence motifs in miRNAs
that guide their sorting into exosomes and showed that
sorting was mediated by sumoylated heterogeneous nu-
clear ribonucleoprotein A2B1 [90]. A study by Koppers-
Lalic et al. suggested that, at least in B cells, sorting of
miRNAs in exosomes depends on the 3′ end modifica-
tions – 3′-end uridylated miRNAs are preferentially
sorted into exosomes, while 3′-end adenylated miRNAs
are retained in cells [91]. At the same time, another
showed that the loading of miRNAs into EVs is mediated
by Annexin A2 in a sequence independent manner [92].
An important question is how EVs secreted by various
cells reach the systemic circulation. After release from
donor cells, EVs may be taken up by neighboring cells,
internalized by the same donor cell or enter the systemic
circulation to reach different tissues. One possible mech-
anism for EV entry into the blood stream could be by
weakening the tight junctions in epithelial/endothelial
barriers. Tight junctions are formed by protein com-
plexes consisting of occludin and claudins, which are tet-
raspanins consisting of 4 transmembrane domains that
form 2 extracellular loops and 1intracellular loop. The
cytosolic C terminus of tetraspanins is linked to adaptor
proteins ZO-1, ZO-2, ZO-3, which interact with the
actin cytoskeleton ensuring the maintenance of tight
junctions and epithelial barrier integrity [93]. In a recent
study Zhou et al. demonstrated that cancer exosome-
derived miR-105 can effectively weaken the tight
junctions between endothelial cells by reducing ZO-1
expression in endothelial cells hence making the endo-
thelial barrier more permeable for cancer cells [94].
Tominaga et al. have provided evidence that actin dy-
namics in the blood-brain barrier (BBB) is altered by
miR-181c transferred by metastatic cancer-derived EVs
[95]. miR-181c promotes the breakdown of BBB through
the downregulation of its target gene, PDPK1, that re-
sults in abnormal localization of actin. Altogether, exoso-
mal miRNAs from cancer cells have been shown to alter
the epithelial/endothelial barrier permeability and may
help EV entry into the systemic circulation.
Cell-free miRNA signatures with diagnostic, prognostic or
predictive relevance for prostate cancer
Following the initial discovery by Mitchell et al. [11] pro-
viding a proof of principle that miRNAs from prostate
cancer cells are released in the bloodstream, where they
are protected against degradation and readily detectable
by PCR-based methods, a number of studies have ex-
plored miRNAs in biofluids of prostate cancer patients.
The levels of specific miRNAs have been correlated with
disease status, stage, aggressiveness and response to
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therapy. The main findings of these studies are sum-
marised in Table 1.
Several groups have performed miRNA profiling in
plasma or serum of patients with localised or metastatic
prostate cancer, BPH and healthy individuals resulting in
the identification of miRNA signatures with remarkably
high diagnostic value. For example, Chen et al. per-
formed miRNA profiling in plasma from patients with
prostate cancer or BPH using Illumina’s miRNA micro-
array and identified a 5 miRNA-model that could differ-
entiate prostate cancer from BPH with AUC of 0.924
and prostate cancer from healthy individuals with AUC
of 0.860 in an independent validation cohort. These
miRNAs were shown to improve the diagnostic perform-
ance of the PSA test [96]. Similarly, by profiling miRNAs
in serum, Haldrup et al. identified another 5 miRNA-
panel that discriminated between prostate cancer and
BPH with AUC of 0.919 [97]. Such miRNAs could po-
tentially aid in early detection of localised prostate can-
cer, however whether or not they can differentiate
clinically significant from indolent cancers remains to be
determined.
A number of studies have identified cell-free miRNAs
that differentiate between localised and metastatic pros-
tate cancer or correlate with the risk score or Gleason
grade. Such miRNAs are potentially associated with ag-
gressive or indolent disease and may aid in tumour sta-
ging and treatment decisions at the time of diagnosis.
For example, a 3 miRNA model comprising miR-141,
miR-151-3p and miR-16 could differentiate localised
prostate cancer from mCRPC with AUC of 0.944 [98].
Another study showed that high levels of miR-146b-3p
and miR-194 in serum could predict rapid biochemical
recurrence after radical prostatectomy in a cohort of 70
patients of intermediate risk according to D’Amico risk
stratification system. Hence these miRNAs could help in
the treatment decisions for intermediate risk localised
prostate cancers [99]. Three other cell-free miRNAs,
miR-106a, miR-93 and miR-1274a were found to be
steadily increased, while miR-24 was steadily decreased
in sera from healthy controls compared to patients with
low and intermediate risk to metastatic disease [100].
Another set of 14 miRNAs was found to be highly
expressed in sera of patients with BPH and low-grade
(100 % Gleason grade 3) prostate cancer while had uni-
formly low levels in patients with high-grade cancers
(Gleason grade 4 and 5) and thus could predict absence
of high-grade cancer with negative predictive value of
0.939 [101]. It has to be noted that there are substantial
discrepancies between studies reporting miRNAs with
prognostic significance. For example, miR-106a, miR-93
and miR-451 have been shown to be highly expressed in
BPH and low-grade cancers compared to high-grade
cancers in one study [101], while the same miRNAs were
shown to be elevated in high-risk cancers as compared
to low-risk cancers and healthy controls in another study
[100]. Whether such differences are due to the different
risk stratification systems or technical variations in
miRNA analysis is not clear at the moment.
A few studies have reported an association of cell-free
miRNA levels with response to therapy. It has been
shown that CRPC patients non-responding to docetaxel
chemotherapy had higher levels of miR-200 family mem-
bers and lower levels of miR-17 family members in
plasma and serum prior to docetaxel therapy, and identi-
fied a 6 miRNA model that could distinguish responders
from non-responders with AUC of 0.730 [102]. Another
study showed that lower serum miR-210 level in mCRPC
patients correlated with PSA response to ADT combined
with chemotherapy and suggested that increased miR-
210 level may serve as a marker for hypoxia response in
the tumour [103].
More recently, several studies have explored the possi-
bility of using other biofluids such as urine or prostatic
secretions as a source of cell-free miRNAs. Guzel et al.
were the first to demonstrate that diagnostically relevant
miRNAs are present in prostate secretions. Three miR-
NAs were significantly downregulated and 1 was upreg-
ulated in prostate secretion samples of prostate cancer
patients compared to BPH, and the combination had an
AUC of 0.950 [14]. This study, was based on a small
sample size and has to be validated in a larger independ-
ent cohort. Urine is an easily accessible sample type that
typically is available in large amounts. Three studies
demonstrated that cell-free miRNAs can be readily de-
tectable in urine and revealed several miRNAs with a
diagnostic significance [15, 57, 104]. Interestingly,
the urinary virus-encoded miRNAs hsv1-miR-H18 and
hsv2-miR-H9-5p could distinguish prostate cancer from
BPH better than the PSA test in patients in the PSA gray
zone and may aid in early detection of localised cancers
[104]. However, urine is just emerging as a novel source
of miRNA biomarkers and currently a direct comparison
of the cell-free miRNA repertoire in blood and urine of
prostate cancer patients is not available. It is too early to
conclude which sample type is more suitable for the de-
tection of miRNA biomarkers.
Most of the studies here presented used total RNA ex-
tracted from whole plasma, serum or other biofluids,
while a few studies focused on EVs. Analysis of the
miRNA profile in exosomes released by prostate cancer
cells revealed a high degree of similarity between the
miRNA of exosomes and parent cells, while a small frac-
tion of miRNAs appeared to be specifically sorted or ex-
cluded from exosomes [105]. Bryant et al. performed
miRNA profiling in MV-enriched EV fractions isolated
from plasma or serum of prostate cancer patients and
controls and identified miRNA panels that were
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Table 1 Studies investigating cell-free miRNA signatures with diagnostic, prognostic and predictive relevance in prostate cancer
Study design, substrate, and sample size Significant miRNAs Diagnostic value/outcome Reference
TaqMan qRT-PCR analysis of 6 candidate
miRNAs in serum from 25 mPC patients and
25 HI. Normalised to spike-ins.
miR-141 AUC = 0.907, Sn = 60 %, Sp = 100 % Mitchell et al.
2008 [11]
miRNA profiling by in serum from 6 PC
patients (stage 3 and 4) and 8 HI by pan-
miRNA microarray.
miR-16, miR-34b, miR-92a, miR-92b, miR-
103, miR-107, miR-197, miR-328, miR-485-
3p, miR-486-5p, miR-574-3p, miR-636,
miR-640, miR-766, miR-885-5p




qRT-PCR analysis of 3 candidate miRNAs in
plasma from 51 PC patients (26 LPC,
25mPC) and 20 HI. Normalized to RNU1A.
miR-21, miR-141, miR-221 miR-21: AUC = 0.880 (PC vs HI) Agaoglu
et al. 2011
[119]miR-221: AUC = 0.830 (PC vs HI)
miR-141: AUC = 0.755 (mPC vs LPC)
Discovery: profiling of 667 miRNAs in serum
of 7 mPC and 14 LPC patients by TaqMan
arrays. Normalised to spike-ins.
miR-141, miR-200b, miR-375 69 differentially expressed miRNAs
between mPC and LPC.
Brase et al.
2011 [120]
Validation 1: analysis of 5 selected miRNA in
different PC risk groups (n = 45).
Increased miR-375, miR-141, miR-200b
levels differentiate pT3 vs pT2, Gleason
score 6 vs 7.
Validation 2: analysis of 3 selected miRNA in
different PC risk groups (n = 71).
miR-375 level differentiate Gleason score 7
vs ≥8 and N0 vs N1/M+
qRT-PCR analysis of 4 candidate miRNAs in
serum from 45 PC, 18 BPH patients and 20
HI. Normalised to spike-ins.
let-7i, miR-26a, miR-32, miR-195 4 miRNA model: AUC = 0.758, Sn = 78,4 %,
Sp = 66.7 % (LPC vs BPH) (PSA AUC = 0.834)
Mahn et al.
2011 [121]
Decrease of miR-26a and miR-195 level
after prostatectomy
Profiling of 384 miRNAs in serum from 36
PC patients (CAPRA scores: 12 low, 12
medium, 12 high risk) and 12 HI using
Fluidigm microfluidic platform, validation of
12 candidate miRNAs by qRT-PCR in the
same sample set.
miR-24, miR-26b, miR-30c, miR-93, miR-
106a, miR-223, miR-451, miR-874, miR-
1207-5p, miR-1274a





miR-106a, miR-93, miR-1274: a liner rela-
tionship between increased miRNA level
and increased risk score.
miR-24: a liner relationship between
decreased miRNA level and increased risk
score.
miR-451: increased in high risk in
comparison to low and medium risk PC
and HI.
qRT-PCR analysis of miR-21 in serum from
56 patients (20 LPC, 20 ADPC, 10 CRPC and
6 BPH) The 10 CRPC patients received
docetaxel-based chemotherapy.
miR-21 A liner relationship between increased
miR-21 level and increased serum PSA level
in patients with ADPC and HRPC.
Zhang et al.
2011 [122]
Higher miR-21 levels in patients who were
resistant to docetaxel-based
chemotherapy.
Profiling of 742 miRNAs in plasma-derived
MVs from 78 PC patients (55 LPC, 16 mPC)
and 28 HI using Exiqon miRNA qPCR panel.
Validation of miR-375 and miR-141 in MV
and exosome fractions from sera of 47 mPC
and 72 non-recurrent PC patients by Taq-
Man qRT-PCR. Normalised to spike-ins.
27 differentially expressed miRNAs miR-107, miR-130b, miR-141, miR-181a-2*,
miR-2110, miR-301a, miR-326, miR-331-3p,
miR-432, miR-574-3p, miRr-625* (PC vs HI).
Bryant et al.
2012 [106]
miR-107, miR-141, miR-181a-2*, miR-2110,
miR-301a, miR-326, miR-432, miR-574-3p,
miR-625* (LPC vs HI).
miR-17*, miR-20a*, miR-23a*, miR-130b,
miR-198, miR-200b, miR-375, miR-379,
miR-513a-5p, miR-572, miR-577, miR-582-
3p, miR-609, miR-619, miR-624*, miR-1236
(mPC vs LPC)
Discovery: profiling of 754 miRNAs in
plasma from 25 PC and 17 BPH patients by
Illumina miRNA expression platform.
Validation: qRT-PCR analysis of 8 selected
miRNAs in plasma from 80 PC, 44 BPH and
54 HI. Normalised to U6.
let-7c, let-7e, miR-30c, miR-622, miR-1285 5 miRNA model: AUC = 0.860, Sn = 74.1 %,
Sp = 83.8 % (PC vs HI)
Chen et al.
2012 [96]
AUC = 0.924 (PC vs BPH)
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Table 1 Studies investigating cell-free miRNA signatures with diagnostic, prognostic and predictive relevance in prostate cancer
(Continued)
Profiling of 365 miRNAs in serum from 25
mCRPC patients (pooled) and 25 HI
(pooled) by TaqMan Low-Density Array.
Normalised to spike-ins. Additional testing
of individual miRNAs by TaqMan qRT-PCR.
miR-141, miR-200a, miR-200c, miR-210,
miR-375




miR-210: correlation with PSA response to
treatment
Profiling of 699 miRNAs in serum samples
from 28 patients of low-risk LPC and 26 of
mCRPC by TaqMan microRNA arrays.
miR-141, miR-375, miR-378*, miR-409-3p Increased levels of miR-375, miR-378* and




miRNA profiling in the serum of 8 patients
with rapid BCR and 8 patients without BCR
following RP. Validation: Testing of four
candidate miRNAs in 70 independent
Gleason 7 PC patient serum samples, 31 of
whom had relapse after RP, by qRT-PCR.
miR-141, miR-146b-3p, miR-194 Increased miRNA levels in serum samples
from patients who had experienced BCR.
Selth et al.
2013 [99]
miR-146b-3p (HR = 2.13) and miR-194 (HR
= 2.13) were also associated with disease
progression in the validation cohort.
qRT-PCR analysis of 4 miRNAs (previously
found deregulated in PC tissues) in urine
samples from 36 PC patients (GS6 and GS7)
and 12 HI. Normalised to RNU48.
miR-205, miR-214 Decreased miRNA levels in PC. miR-205:




2 miRNA model: Sn = 89 %, Sp = 80 %
Profiling of 742 miRNAs in plasma samples
from 25 LPC (pooled) and 25 mCRPC
(pooled) patients by Exiqon miRNA qPCR
panel. Validation: Analysis of 10 selected
candidate miRNAs in 50 individual plasma
samples by qRT-PCR.
miR-16, miR-141, miR-151-3p 67 differentially expressed miRNAs. Watahiki
et al. 2013
[98]3 miRNA model : AUC = 0.944, Sn = 84 %,
Sp = 96 %
Profiling of 732 miRNAs in serum samples
from 13 BPH and 31 PC (11 LPC + 9 N1/M1
+ 11 CRPC) patients by Exiqon microRNA
PCR panel I + II, V2.M.
19 differentially expressed miRNAs miR-562/miR-210/miR-501-3p/miR-375/
miR-551b model: AUC = 0.919, Sn = 84 %,




model: AUC = 0.875, Sn = 75 %, Sp = 100 %
(LPC vs disseminated PC)
let-7a/miR-210/miR-562/miR-616/miR-297
model: AUC = 0.900, Sn = 80 %, Sp = 100 %
(BPH vs disseminated PC)
miRNA profiling on docetaxel-resistant and
sensitive cell lines to identify candidate cir-
culating miRNA biomarkers and subsequent
qRT-PCR analysis of 46 candidate miRNAs in
plasma/serum samples collected from 97
CRPC patients before and after docetaxel
treatment.
miR-20a, miR-20b, miR-21, miR-25, miR-
132, miR-146a, miR-200a, miR-200b,
miR-200c, miR-201b, miR-222, miR-375,
miR-429, miR-590-5p
miR-200c/miR-200b/miR-146a/miR-222/
miR-201b/miR-20a model for prediction of
chemoresponse: AUC = 0.730
Lin et al.
2014 [102]
Pre-docetaxel levels of miR-200b, miR-429,
miR-200a, miR-21, miR-200c, miR-590-5p,
miR-375, miR-132, miR-20a and post-
docetaxel decrease/no-change of miR-20a,
miR-222, miR-20b, miR-132 and miR-25 as-
sociated with poor overall survival.
miRNA profiling in PSS from 4 BPH patients
and 4 PC patients by Agilent miRNA
Microarray.
miR-133b, miR- 203, miR-221, miR-361-3p 4 miRNA model: AUC = 0.950 Guzel et al.
2015 [14]
Validation: Analysis of 4 candidate miRNA in
PSS from 23 PC and 25 BPH patients by
qRT-PCR.
Deep sequencing of plasma exosomal RNA
in 23 CRPC patients and correlation with
OS. Validation: qRT-PCR analysis of candi-
date miRNAs in a follow-up cohort of 100
CRPC patients.




Combination of ADT failure time and PSA
level at time of CRPC stage with miRNA
levels improved predictive performance
with AUC increase from 0.660 to 0.730.
qRT-PCR analysis of 12 miRNAs in blood
and tissue samples from 75 PC and 27 BPH
patients
let-7a, miR-141, miR-145, miR-155 4 miRNA model: AUC = 0.783, Sn = 97 %,
PPV = 80 %
Kelly et al.
2015 [123]
qRT-PCR analysis of 3 candidate miRNAs in
cell-free urine fraction from 71 PC patients
and 18 HI.





Endzeliņš et al. Molecular Cancer  (2016) 15:41 Page 8 of 13
differentially expressed between prostate cancer patients
and healthy controls or between patients with localised
and metastatic cancer [106]. These panels included some
miRNAs (such as miR-141, miR-107, miR200b and miR-
375) that had previously been found in studies of whole
plasma or serum, yet the majority of the miRNAs did
not overlap with other studies. Interestingly, miR-141
and miR-375 had similar expression patterns both in
MV and exosome-enriched EV fractions [106]. Huang et
al. performed deep sequencing of exosomal RNAs in
CRPC patients and identified two miRNAs – miR-375
and miR-1290 that were significantly associated with
overall survival and thus may aid in the treatment deci-
sions for CRPC patients [107]. These studies show that
miRNA analysis in various EV fractions isolated from
blood is feasible, however, whether or not EV-based ana-
lysis provides any advantages over whole plasma or
serum analysis is not yet clear.
Technical challenges in testing cell-free miRNAs
Some cell-free miRNAs, including miR-141, miR-375,
miR-21, miR-107 and miR-221, have been identified in
multiple studies that strongly support their relevance as
prostate cancer biomarkers. However, more than a half
of the miRNAs have been associated with prostate can-
cer diagnosis or prognosis only in 1 study and others
have been reported to have opposite prognostic roles.
This could be attributed to some extent to variations in
pre-analytical and analytical techniques for miRNA
analysis.
Although initial studies suggested that serum and
plasma miRNAs remain stable and protected from
degradation after treatment with exogenous RNase A,
several freeze-thaw cycles and extreme pH conditions
[11, 12], later studies show that blood processing con-
ditions may substantially influence cell-free miRNA
levels [108]. A major factor affecting miRNA abun-
dance appears to be a residual platelet contamination.
It has been shown to affect the levels of 72 % of circu-
lating miRNAs, and some of them exhibited even
1000-fold variation solely due to differences in pro-
cessing [108]. The platelet count is likely to be af-
fected by centrifugation conditions, variations in
blood collection procedure and storage conditions.
Furthermore, thrombocytosis is commonly found in
cancer patients and has been associated with poor
prognosis in various cancers [109, 110], and thus may
cause a systematic bias in case-control studies [108].
In addition, levels of some miRNAs have also been
shown to be affected by haemolysis [111]. This empha-
sizes the importance of rigorously standardised proce-
dures for blood collection and processing, as well as
controlling for haemolysis and platelet counts in stud-
ies investigating cell-free miRNAs. Factors affecting
miRNA abundance and stability in other biofluids
should also be systematically studied.
The choice of reference genes and/or normalisation
method for qRT-PCR can also cause a systematic bias
and inconsistency in the quantification of cell-free miR-
NAs. Compared to miRNA expression analysis in tis-
sues, where the selection of internal controls for data
normalisation is relatively straight-forward and panels of
reliable controls have been established, there is no con-
sensus on the most appropriate normalisation method
for the quantification of cell-free miRNAs in biofluids.
The most commonly used internal controls such as
rRNAs, snoRNA, RNU6B and miR-16 have been shown
to be highly variable in biofluids [112–114]. Therefore,
many studies are using “spike-ins” – synthetic RNAs
with no sequence homology to human miRNAs that
are spiked into the biofluid sample prior to RNA ex-
traction and amplified together with the target miR-
NAs. Spike-ins can control for variations arising during
RNA extraction, reverse transcription and PCR effi-
ciency, but cannot detect variations caused by platelet
contamination or haemolysis. Several recent studies
have made attempts to identify reliable internal con-
trols in various biofluids by analysing large-scale ex-
pression datasets. For example, Schlosser et al.
performed global profiling of miRNAs in plasma from
Table 1 Studies investigating cell-free miRNA signatures with diagnostic, prognostic and predictive relevance in prostate cancer
(Continued)
Discovery: miRNA profiling in cell-free urine
from 14 PC and 5 BPH patients. Validation:
qRT-PCR analysis of candidate miRNAs in
urine in 3 validation cohorts including 593
PC patients and 459 controls.
Hsv1-miR-H18, hsv2-miR-H9-5p Hsv1-miR-H18: AUC = 0.772, Sn = 66.5 %,
Sp = 74.1 %
Yun et al.
2015 [104]
Hsv2-miR-H9-5p: AUC = 0.777, Sn = 70.2 %,
Sp = 72.0 %
qRT-PCR analysis of 21 miRNA in serum
from 50 low-grade (Gleason grade 3) PC
and 50 high grade (Gleason grade 4 + 5)
PC.
let-7a, miR-24, miR-26b, miR-30c, miR-
93, miR-100, miR-103, miR-106a, miR-
107, miR-130b, miR-146a, miR-223, miR-
451, miR-874
Highly expressed in BPH and low-grade PC,
uniformly low levels in high-grade PC. 11
miR model: NPV of 0.939 for prediction of




ADPC androgen-dependent prostate cancer, BCR biochemical recurrence, BPH benign prostatic hyperplasia, CRPC castration resistant prostate cancer, GS Gleason
score, HI healthy individuals, mPC metastatic prostate cancer, LPC localised prostate cancer, MV microvesicle, PC, prostate cancer, PSS prostate secretion samples,
qRT-PCR quantitative reverse transcription-polymerase chain reaction, RP radical prostatectomy, Sn sensitivity, Sp specificity. miRNAs identified in more than one
study are marked in bold
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pulmonary hypertension patients and healthy subjects
and identified miR-142-3p and miR-320a as the most
suitable internal controls, however it remains to be de-
termined if these miRNAs are suitable controls in other
diseases [114]. Huang et al. analysed RNA sequencing
data from plasma exosomal RNAs in 192 subjects and
found miR-30a-5p and miR-30e-5p as the best en-
dogenous controls for data normalisation [107]. Finding
a suitable internal control for urinary miRNA analysis
seems to be even more challenging. Given that urine
samples vary greatly in their concentration and volume,
spike-ins are unlikely to be a suitable approach. Some
of the commonly used controls such as miR-16, RUN6-
2, miR-518a and miR-3605 exhibited large variation be-
tween urine samples and therefore are not suitable as
urinary reference genes. Thus, at the moment, normal-
isation to the total RNA concentration seems to be the
most reliable approach [104].
Conclusions
Eight years ago cell-free miRNAs emerged as an entirely
new type of cancer biomarkers detectable in human bio-
fluids. Since then, a number of cell-free miRNAs that
may serve as biomarkers of prostate cancer has been dis-
covered. Most of them are putative diagnostic or prog-
nostic biomarkers that may aid in early detection or help
to distinguish aggressive cancers from indolent cancers.
To date, far less predictive biomarker candidates that
may aid in therapeutic choices for advanced cancers
have been discovered.
The sample sizes are relatively small in most of the
studies and the identified miRNA biomarkers should be
validated in cohorts with adequate statistical power and
in a clinically relevant setting. Biomarkers that are ex-
pected to detect early-stage cancers or be associated
with aggressiveness should be evaluated in longitudinal
studies to assess at what time point during disease devel-
opment a candidate biomarker becomes detectable in
biofluids. This would show if a putative prognostic bio-
marker appears in the biofluid only when the cancer
already has metastasized or before the clinically detect-
able metastases appear, and therefore could predict the
disease behaviour. Next, the performance of a biomarker
assay should be evaluated in a blinded, randomised clin-
ical trial, before it can be used in a clinical setting.
Most studies have explored cell-free miRNAs in blood.
However, several recent studies demonstrated that
cancer-associated cell-free miRNAs can also be detected
in other biofluids, such as urine or prostate secretions,
which potentially may be enriched in cancer-derived
miRNAs and have a lower background of miRNAs re-
leased by various normal cells. To evaluate which bio-
fluid is the best source of prostate cancer-associated
miRNAs, a systematic comparison of miRNA profiles in
blood, urine, prostate secretions and cancer tissues of
the same patient is required.
It has been suggested that purified EVs may have sev-
eral advantages over whole-plasma (or other biofluid)
analysis since they may contain cancer-associated
miRNA signatures and provide better protection against
degradation. In addition, prostate cancer-derived exo-
somes have been shown to be enriched in PSMA [115],
a prostate-specific membrane antigen that is upregulated
in a vast majority of prostate cancers [116]. Hence,
PSMA might serve as a tool for detection and isolation
of prostate cancer-derived exosomes from biofluids.
This, in turn, could enable the analysis of cancer-derived
miRNAs and other nucleic acids without contamination
of those derived from normal cells. Nevertheless, it is
still an open question what type of EVs represents the
best source of miRNA biomarkers and whether EV
isolation can improve the detection of prostate
cancer-associated miRNAs in biofluids. A head-to-
head comparison of EV-based versus whole biofluid-
based techniques would be highly relevant to address
this question.
The cellular origin of cell-free miRNAs is also an im-
portant aspect. Initial studies suggested that the majority
of cell-free miRNAs in the blood of healthy individuals
is released from blood cells, while disease-associated
miRNA signatures may be derived from the tissues af-
fected by the disease [11, 12]. Several miRNAs, such as
miR-141, miR-375, miR-200a, miR-200c and miR-210,
which were found at elevated levels in blood of prostate
cancer patients, have also been shown to be overex-
pressed in prostate cancer tissues [103, 117], suggesting
that these circulating miRNAs originate from prostate
cancer tissues. However, no such correlation has been
found for other miRNAs, such as miR-378* and miR-
409-3p [117]. The cellular origin of miRNAs that are
decreased in biofluids is even more controversial as the
decrease is very unlikely to be related to their expression
level in tumour tissues. Instead, it might be associated
with inflammatory or immune responses to the tumour.
Taking together, these studies suggest that cell-free
miRNAs are a novel and very attractive type of cancer
biomarkers. Gaining a deeper understanding of the ques-
tions arising from the initial studies will help to design
future miRNA biomarker discovery studies, assess the
identified biomarker candidates and select the best can-
didates for evaluation in clinical trials.
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